| Heading: |
Cerliponase Alfa |
| Question ID: |
1762678 |
| UIN: |
29367 |
| House: |
Commons |
| Date tabled: |
2025-02-05 |
| Asking Member ID: |
5191 |
| Asking Member display name: |
Adam Dance
|
| Asking Member handle: |
|
| Asking Member Twitter reference: |
Adam Dance
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, what progress has been made on the negotiations with Biomarine on the provision of Brineura as a treatment for Batten disease. |
| Is named day: |
true |
| Date of holding answer: |
|
| Date answered: |
2025-02-10 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
The National Institute for Health and Care Excellence (NICE) is currently developing guidance for the National Health Service on whether Brineura (cerliponase alfa) can be recommended for routine NHS funding, taking into account real-world evidence collec... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |